China's Kindstar Globalgene H1 loss narrows after oncology testing expansion

Kindstar Globalgene Technology

26/08/2026 23:35

Overview
China diagnostics testing firm's H1 revenue rose 3.7% yr/yr 
Net loss for H1 narrowed 44.7% yr/yr as gross profit margin improved
Company cites stable core segment performance and oncology testing expansion for revenue growth

Outlook
Company did not provide specific financial guidance for future periods in press release

Result Drivers
ONCOLOGY TESTING EXPANSION - Co said rapid expansion of its oncology testing segment delivered significant incremental revenue and became a new growth engine
CORE SEGMENT STABILITY - Hematology testing, as core segment, maintained stable performance and underpinned revenue
COST CONTROL - Stringent cost control measures reduced operating expenses, supporting improved profitability

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
RMB 473.60 mln
 
H1 Net Loss Attributable
 
RMB 18.10 mln
 

Analyst Coverage
The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 9 three months ago

Reuters Recommended Reads
Aug 26 - Grand Pharmaceutical H1 revenue rises on nuclear medicine demand
Aug 25 - China's Weigao H1 profit falls 23% as price drops, competition hit margins
Aug 26 - China's Zhongzhi Pharmaceutical H1 revenue falls 10%

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)